Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC)
    Meeting Abstract

    Anand, A.; Morris, M. J.; Larson, S. M.; Ohlsson, M.; Joseffson, A.; Helgstrand, J. T.; Edenbrandt, L.; Oturai, P. S.; Roeder, M. A.; Bjartell, A.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM
    Meeting Abstract

    Armstrong, A. J.; Saad, F.; Shore, N. D.; Fizazi, K.; Phung, D.; Dmuchowski, C. F.; Hirmand, M.; Forer, D.; Scher, H. I.; De Bono, J. S.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Garcia, J. A.; Alva, A. S.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Summa, J. M.; Youssoufian, H.; Scher, H. I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Actionable targets in patients with cisplatin-resistant advanced germ cell tumors
    Meeting Abstract

    Bagrodia, A.; Kaffenberger, S. D.; Lee, B.; Lee, W.; Cha, E. K.; Sfakianos, J.; Gao, S. P.; Zabor, E. C.; Ostrovnaya, I.; Eng, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice
    Journal Article

    Philp, L. K.; Day, T. K.; Butler, M. S.; Laven-Law, G.; Jindal, S.; Hickey, T. E.; Scher, H. I.; Butler, L. M.; Tilley, W. D.
    Scientific Reports (2016)

    Fulltext@MSK | Save
  • Integrating genomics onto clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center
    Journal Article

    Ortiz, M. V.; Kobos, R.; Walsh, M.; Slotkin, E. K.; Roberts, S.; Berger, M. F.; Hameed, M.; Solit, D.; Ladanyi, M.; Shukla, N.; more...
    Pediatric Blood and Cancer (2016)

    Fulltext@MSK | Save
  • A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma
    Journal Article

    Carlo, M. I.; Molina, A. M.; Lakhman, Y.; Patil, S.; Woo, K.; Deluca, J.; Lee, C. H.; Hsieh, J. J.; Feldman, D. R.; Motzer, R. J.; more...
    The Oncologist (2016)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors
    Journal Article

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Lim, K.; Patil, S.; Woo, K. M.; Carousso, M.; Hughes, A.; Sheinfeld, J.; Bains, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Selenium- or vitamin E-related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT
    Journal Article

    Chan, J. M.; Darke, A. K.; Penney, K. L.; Tangen, C. M.; Goodman, P. J.; Lee, G. S. M.; Sun, T.; Peisch, S.; Tinianow, A. M.; Rae, J. M.; more...
    Cancer Epidemiology Biomarkers and Prevention (2016)

    Fulltext@MSK | Save
  • Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
    Journal Article

    Nadal, R.; Amin, A.; Geynisman, D. M.; Voss, M. H.; Weinstock, M.; Doyle, J.; Zhang, Z.; Viudez, A.; Plimack, E. R.; McDermott, D. F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save